| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Division of Emergency Medicine (Dr. Weber), University of California San Francisco; Department of Emergency Medicine (Dr. Levitt), Alameda Medical Center, Highland Campus, Oakland, CA; and the Respiratory Care Department (Mr. Covington and Ms. Gambrioli), University of California San Francisco.
Objective: To compare the outcome of patients with acute bronchospasm treated with continuously nebulized albuterol plus ipratropium bromide vs albuterol alone.
Setting: The Emergency Department (ED) at the University of California San Francisco Medical Center.
Participants: Patients 
18 years
old presenting to the ED with acute bronchospasm and a peak expiratory
flow rate (PEFR) of < 70% predicted.
Interventions: This was a prospective, randomized, double-blind, placebo-controlled trial. Subjects were treated with either a combination of albuterol (10 mg/h) plus ipratropium bromide (1.0 mg/h) or albuterol alone via continuous nebulization for a maximum of 3 h. Vital signs, Borg dyspnea score, and PEFR were recorded hourly. Primary outcome measures were improvement in PEFR, hospital admission rates, and length of stay in the ED.
Measurements and results: Data was analyzed for 67 subjects. The mean age (± SD) was 47.5 ± 18.8, and mean initial PEFR was 44.8 ± 12.5% of predicted. The median length of stay for all subjects was 225 min, and 31% of all subjects were admitted. Patients given combination therapy averaged 6.3% greater improvement in PEFR compared with control subjects (95% confidence interval [CI], -15% to 27%. The odds ratio for admission with combination therapy was 0.88 (95% CI, 0.28 to 2.8). The median length of stay in the ED was 35 min shorter for those receiving combination treatment (210 vs 245 min; p = 0.03). However, when adjusted for initial PEFR, there was no statistically significant difference (p = 0.26).
Conclusion: Although the direction of all three outcome measures favored combination therapy, there was no statistically significant difference between ED patients with acute bronchospasm receiving continuous albuterol plus ipratropium bromide and those receiving albuterol alone.
Key Words: acute disease • albuterol administration and dosage/therapeutic use • asthma • chronic obstructive pulmonary disease • comparative study • emergency service • hospitals • ipratropium administration and dosage/therapeutic use • treatment outcome
This article has been cited by other articles:
|
|
 |
|
  G J Rodrigo and J A Castro-Rodriguez Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis Thorax, September 1, 2005; 60(9): 740 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. McFadden Jr. Acute Severe Asthma Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Rodrigo, C. Rodrigo, M. Noppen, and R. Silverman IV Magnesium in the Treatment of Acute Severe Asthma? Chest, April 1, 2003; 123(4): 1314 - 1316. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Rodrigo and C. Rodrigo The Role of Anticholinergics in Acute Asthma Treatment* : An Evidence-Based Evaluation Chest, June 1, 2002; 121(6): 1977 - 1987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. RODRIGO and C. RODRIGO First-Line Therapy for Adult Patients with Acute Asthma Receiving a Multiple-Dose Protocol of Ipratropium Bromide Plus Albuterol in the Emergency Department Am. J. Respir. Crit. Care Med., June 1, 2000; 161(6): 1862 - 1868. [Abstract] [Full Text]
|
|
|
|
 |
|
 Adding Ipratropium to Albuterol Does Not Improve Asthma Journal Watch Emergency Medicine, July 1, 1999; 1999(701): 1 - 1. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
